Platform
Binders
Team
Pipeline
Media
Join Us
Contact
For Patients
Platform
Binders
Team
Pipeline
Media
Join Us
Contact
For Patients
Media
Press Release
May 23 2025
Verismo Therapeutics Provides Updates on Upcoming Poster Presentation at ASCO 2025
MORE >
Press Release
April 24 2025
Verismo Therapeutics Announces Poster Presentation at ASCO 2025
MORE >
Press Release
January 10 2025
Verismo Therapeutics Announces First Patient Infused in Phase 1 CELESTIAL-301 Clinical Trial of SynKIR™-310
MORE >
Press Release
January 7 2025
Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma
MORE >
Press Release
December 20 2024
Verismo Therapeutics Completes Merger to Accelerate Clinical Development
MORE >
Press Release
October 8 2024
Verismo Therapeutics Announces the Activation of its CELESTIAL-301 Clinical Trial at Colorado Blood Cancer Institute
MORE >
Press Release
September 17 2024
Verismo Therapeutics Awarded a ScaleReady™ G-Rex® Grant
MORE >
Press Release
May 14 2024
Verismo Therapeutics Receives IND Clearance from the FDA for SynKIR™-310 in Relapsed/Refractory B-cell NHL
MORE >
Press Release
May 6 2024
Verismo Therapeutics Announces Upcoming Presentation at ASGCT 2024
MORE >
Press Release
April 3 2024
Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR™-310 in Relapsed/Refractory B-cell NHL
MORE >
Next Page
